CClinicalTrials.gg
CompletedNCT04886323ECAPMFUpdated Dec 26, 2023

Effect of Cold Atmospheric Plasma on Malassezia Folliculitis

An interventional study of Cold atmospheric plasma treatment device and Itraconazole Capsules in Malassezia Folliculitis, sponsored by The Second Hospital of Anhui Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by The Second Hospital of Anhui Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The cold atmospheric plasma may provide a new and effective method for the treatment of Malassezia folliculitis. The investigators conduct this randomized controlled trial to evaluate the effectiveness and safety of cold atmospheric plasma on Malassezia folliculitis. Participants entered this double-blind placebo-controlled trial will randomly assign to treatment with either cold atmospheric plasma or antifungal drugs. The differences of treatment effects of the two groups will be observed and compared.

Read the detailed description

Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are limited due to adverse drug reactions and drug resistance. Cold atmospheric plasma has an inhibitory or killing effect on pathogenic microorganisms including fungi and has no obvious adverse damage to normal tissues. The investigators conduct this randomized controlled trial to study the effect of cold atmospheric plasma on Malassezia folliculitis, and evaluate its effectiveness and safety for Malassezia folliculitis. All data are recorded and compared after the end of the experiment.

02

Conditions studied

  • Malassezia Folliculitis

Keywords

  • Malassezia
  • Malassezia folliculitis
  • Cold atmospheric plasma
  • Pityrosporum folliculitis
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients are clinical presentation of Malassezia folliculitis in seborrheic areas.
  • The diagnoses are mycologically verified by experienced laboratory technicians.
  • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Combined with other serious systemic diseases.
  • History of topical corticosteroids within 2 weeks or history of systemic corticosteroids within 1 month.
  • History of immunosuppressive drugs within 1 month.
  • History of topical antifungal medication within 2 weeks or systemic antifungal medication within 3 months.
  • Pregnant and lactating women.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    cold atmospheric plasma treatment group

    Patients are treated with a plasma device. Each treatment time was 3min per area based on the lesion size.The frequency of treatment is once a day. The duration of the treatment period is 2weeks.

    Device: Cold atmospheric plasma treatment device

  • Active comparator
    Itraconazole capsules treatment group

    Patients are treated with Itraconazole capsules, 200mg a day.The duration of the treatment period is 2weeks.

    Drug: Itraconazole Capsules

Interventions

  • DeviceCold atmospheric plasma treatment device

    Treat with cold atmospheric plasma treatment device.

  • DrugItraconazole Capsules

    Treat with Itraconazole capsules

05

What researchers measure

Primary outcomes

  1. 50% reduction in number of lesion

    proportion of subjects who achieve at least a 50% reduction in total number of lesions

    Time frame: week 2

Secondary outcomes

  1. proportion of subjects in physician's global assessment.

    proportion of subjects who achieve a physician's global assessment 0 / 1.

    Time frame: week 2

06

Study locations

1 site
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
07

References and documents

Publications

  • Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM; Danish Society of Dermatology. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015 Jan;95(1):12-9. doi: 10.2340/00015555-1825. PubMed 24556907 ↗
  • VON Woedtke T, Schmidt A, Bekeschus S, Wende K, Weltmann KD. Plasma Medicine: A Field of Applied Redox Biology. In Vivo. 2019 Jul-Aug;33(4):1011-1026. doi: 10.21873/invivo.11570. PubMed 31280189 ↗
  • Wiegand C, Fink S, Hipler UC, Beier O, Horn K, Pfuch A, Schimanski A, Grunler B. Cold atmospheric pressure plasmas exhibit antimicrobial properties against critical bacteria and yeast species. J Wound Care. 2017 Aug 2;26(8):462-468. doi: 10.12968/jowc.2017.26.8.462. PubMed 28795887 ↗
  • Gao J, Wang L, Xia C, Yang X, Cao Z, Zheng L, Ko R, Shen C, Yang C, Cheng C. Cold atmospheric plasma promotes different types of superficial skin erosion wounds healing. Int Wound J. 2019 Oct;16(5):1103-1111. doi: 10.1111/iwj.13161. Epub 2019 Jun 17. PubMed 31207094 ↗
  • Parsad D, Saini R, Negi KS. Short term treatment of pityrosporum folliculitis with itraconazole. Indian J Dermatol Venereol Leprol. 1999 May-Jun;65(3):122-3. PubMed 20921630 ↗
  • Lee JW, Kim BJ, Kim MN. Photodynamic therapy: new treatment for recalcitrant Malassezia folliculitis. Lasers Surg Med. 2010 Feb;42(2):192-6. doi: 10.1002/lsm.20857. PubMed 20166153 ↗
  • Abdel-Razek M, Fadaly G, Abdel-Raheim M, al-Morsy F. Pityrosporum (Malassezia) folliculitis in Saudi Arabia--diagnosis and therapeutic trials. Clin Exp Dermatol. 1995 Sep;20(5):406-9. doi: 10.1111/j.1365-2230.1995.tb01358.x. PubMed 8593718 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04886323
Lead sponsor
The Second Hospital of Anhui Medical University
Collaborators
Hefei CAS Ion Medical and Technical Devices Co.,Ltd
Responsible party
Yang chunjun (Head of Dermatology, The Second Hospital of Anhui Medical University) — Principal investigator
First posted
May 14, 2021
Start date
Aug 3, 2022
Primary completion
Dec 17, 2023
Completion
Dec 17, 2023
Last update
Dec 26, 2023

Study contacts

Chunjun Yang
study chair · The Second Hospital of Anhui Medical University
Na Wang
study director · The Second Hospital of Anhui Medical University
Jingwen Wang
principal investigator · The Second Hospital of Anhui Medical University
Jing Gao
principal investigator · The Second Hospital of Anhui Medical University
Liyun Wang
principal investigator · The Second Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion